Research & Development



  按理說,到了這個時候,司馬遷應該替尊者隱諱,不再提這件事了。   “不會的,小郎君會來,小小郎君也會來,大將軍也會回來。”日本www.在线中文字幕   然後掃視一遍周邊的諸侯王一眼,非常的得意,話里話外的意思都是郡縣制必須推行天下,而且是順者生,逆者死,希望諸侯王能夠向他學習,把自己的封國也獻給皇帝。夜夜嚕2017最新在线 第一五八章 劉徹的瑜伽天女   劉徹很希望自己的臣子們能夠滿足于現在擁有的一切,然而,他又知道,人類追求成功的欲望永遠沒有止境,貪婪之心永遠滿足的時候。2018天天看夜夜看   離開了長平侯府搬回長公主府之後,公主就很少說話,臉上也不見歡顏。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo